 Home > Active Ingredient News > Study of Nervous System > JPD: Levodopa-carbidopa intestinal gel for Parkinson's disease, quality of life and symptoms?

JPD: Levodopa-carbidopa intestinal gel for Parkinson's disease, quality of life and symptoms?

 Last Update: 2022-02-19
 Source: Internet
 Author: User

Tags

advanced health solutions

etchant gel

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Levodopa is the gold standard for the treatment of Parkinson's disease (PD), but it has a short plasma half-life and may cause motor fluctuations and dyskinesias
.

One way to address the short half-life of levodopa in patients with advanced Parkinson's disease is to develop levodopa-carbidopa enteric gel (LCIG) for continuous infusion of levodopa

Quality of Life

Several studies have shown that motor symptoms and dyskinesia have a large impact on HRQoL
.

However, results from other studies showed no or only weak associations, and some were limited by method and statistics .

statistics

DUOdopa/Duopa in Patients with Advanced Parkinson's Disease -- the GLobal OBservational Study to Assess Long-Term Efficacy (DUOGLO BE) -- is an ongoing long-term efficacy study of LCIG in practice
.

While the study is still ongoing, results from a second interim analysis of LCIG's safety and efficacy have been published

From this, Norbert Kovacsa et al.
, dUniversity of Pecs, explored the relationship between HRQoL and measures of PD severity and treatment effect, including motor and non-motor symptoms
.

A total of 195 patients were included
.

At baseline, HRQoL was moderately positively correlated with activities of daily living (UPDRS II, PCC=0.

Improvements in HRQoL after 12 months of treatment with LCIG were moderately positively correlated with improvements in non-motor symptoms (PCC=0.
42), sleep (0.
54), and daytime sleepiness (0.
40), and with improvements in dyskinesia symptoms and signs.
Weak correlation (PCC=0.
23; P=0.
011)
.

Improvements in HRQoL were not associated with improvements in OFF time or dyskinesia time
.

The significance of the study is that it found that HRQoL was associated with both baseline and baseline changes in dyskinesia, activities of daily living, and non-motor symptoms (including sleep), both at baseline and at 12 months ; but not with baseline or OFF Changes in time are irrelevant
.

HRQoL was associated with both baseline and baseline changes in dyskinesia, activities of daily living, and non-motor symptoms (including sleep), both at baseline and at 12 months

Original source:
Kovacs N, Bergmann L, Anca-Herschkovitsch M, et al.

Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
.

Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
.
Outcomes Impacting Quality of Life in Advanced Parkinson's Disease Patients Treated with Levodopa-Carbidopa Intestinal Gel.
.
Leave a Comment

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.